Results 1 to 10 of about 374,365 (198)

Use of Depot Medroxyprogesterone Acetate and Fracture Risk [PDF]

The Journal of Clinical Endocrinology & Metabolism, 2010
Depot medroxyprogesterone acetate (DMPA), which has a high rate of use among teenagers in Europe and the United States, has been associated with impaired bone mineral acquisition during adolescence and accelerated bone loss in later life. Studies on the association between DMPA use and fracture risk are limited.We aimed at evaluating the relationship ...
Meier, Christian, Brauchli, Yolanda B., Jick, Susan S., Kraenzlin, Marius E., Meier, Christoph R.   +4 more
openaire   +6 more sources

The Risk of Infection Human Papilloma Virus Infection in Acceptors of Depot Medroxyprogesterone Acetate Contraceptions [PDF]

Indonesian Journal of Obstetrics and Gynecology, 2018
Objective: Cervical cancer is the second most prevalent cancer in women around the world and the most common cancer in women causing death. This study aims to analyze the connection between infection of human papilloma virus (HPV) 16/18 and cervical ...
Baharuddin Aras, Mardiah Tahir, Sharvianty Arifuddin, Eddy Hartono, Maisuri T. Chalid   +4 more
doaj   +2 more sources

Combined high dose vitamin C and E increases oxidative stress and visceral fat mass in rats treated by depot-medroxyprogesterone acetate

Middle East Fertility Society Journal, 2016
Objective: This study was aimed to investigate the effect of combined vitamin C and E on serum leptin, visceral fat mass, and visceral fat oxidative stress in rats treated by depot-medroxyprogesterone acetate (DMPA).
Endang Sri Wahyuni, I. Wayan Arsana Wiyasa, Nurdiana Nurdiana   +2 more
doaj   +2 more sources

A Comparative Evaluation of Cut 380A Intrauterine Device Versus Depot Medroxyprogesterone Acetate For Long-Acting Reversible Contraception [PDF]

Journal of Pharmacy and Bioallied Sciences
Background: India’s family-planning program increasingly emphasizes long-acting reversible contraceptives (LARCs) to curb unintended pregnancy. Copper T 380A (CuT 380A) intrauterine device (IUCD) and injectable depot medroxyprogesterone acetate (DMPA ...
Manisha Meena, Rupali Dewan
doaj   +2 more sources

Self-administered subcutaneous medroxyprogesterone acetate for improving contraceptive outcomes: a systematic review and meta-analysis

BMC Women's Health, 2021
Background Subcutaneous depot medroxyprogesterone acetate is an easy-to-use injectable contraceptive. A trained person can administer it, including women through self-injection.
Ashraf Nabhan, Farida Elshafeey, Luna Marion Mehrain, Rita Kabra, Amal Elshabrawy   +4 more
doaj   +1 more source

Effectiveness and follow-up of depot medroxyprogesterone acetate in postpartum and postabortal patients

National Journal of Physiology, Pharmacy and Pharmacology, 2023
Background: Contraception is the intentional use of artificial methods or other techniques to prevent pregnancy as a consequence of sexual intercourse. Progesterone only injectables are highly effective in preventing in pregnancy as they do not rely on ...
Jayun M Joshi, Harsh M Joshi, Hetal Patel, Param S Patel   +3 more
doaj   +1 more source

Effect of depot-medroxyprogesterone acetate injections on serum immunoglobulins and complements level [PDF]

المجلة العراقية للصيدلة, 2008
Background: Depot medroxyprogesterone acetate (Depo-Provera) is a highly effective, nondaily hormonal contraceptive option that has been available in the worldwide for 40 years and provides a very high level of contraceptive efficacy. Benefits and risks
Wahda B. Al-Youzbaki
doaj   +1 more source

The effect of Vigna unguiculata on the estrogen receptor-α expression and the endometrial thickness in rats treated with depot medroxyprogesterone acetate (DMPA)

Healthcare in Low-resource Settings, 2023
Depot medroxyprogesterone acetate (DMPA) is a contraceptive method that prevents ovulation and reduces endometrial thickness. This study aimed to investigate the influence of Vigna unguiculata (VU) on estrogen receptor-α expression and endometrial ...
Rizki Fitrianingtyas, Indah Christiana, Ririn Handayani, Ernawati Anggraeni, Zaida Mauludiyah, Sholihatil Hidayati   +5 more
doaj   +1 more source

Contraceptive effectiveness, pharmacokinetics, and safety of Sayana® Press when injected every four months: a multicenter phase 3 trial

EClinicalMedicine, 2022
Summary: Background: Sayana Press® is a 3-monthly contraceptive injection approved by regulatory agencies in more than 40 countries worldwide. Existing effectiveness and pharmacokinetics (PK) data suggest that high contraceptive efficacy may be ...
Jennifer Deese, Vivian Brache, Luis Bahamondes, Abril Salinas, Aidelis Jorge, Nelio Veiga, Jr, Rachael Fuchs, Ashley Miller, Doug Taylor, Vera Halpern, Laneta Dorflinger   +10 more
doaj   +1 more source

Sexual Dysfunction in Two Types of Hormonal Contraception: Combined Oral Contraceptives versus Depot Medroxyprogesterone Acetate [PDF]

Journal of Midwifery & Reproductive Health, 2017
Background & aim: Sexual health is an essential element of quality of life, affecting both physical and psychological domains. Hormones used in contraceptive methods have contradictory effects on sexual function. In this study, we aimed to compare sexual
Nourossadat Kariman, Zohre Sheikhan, Masoumeh Simbar, Alireza Zahiroddin, Alireza Akbarzadeh Bahgban   +4 more
doaj   +1 more source